Dr. Rivella is an expert in the pathophysiology of erythroid and iron disorders and in the generation of lentiviral vectors for the cure of hemoglobinopathies. He also investigates additional disorders such as anemia of inflammation and hemochromatosis.
Dr. Olson aims to improve diagnostics and treatment of bone marrow failure (BMF) syndromes, and to improve clinical hematopoietic stem cell transplantation (HSCT) outcomes. He conducts clinical trials of HSCT for non-malignant hematologic diseases. His laboratory explores both basic and translational research focused on genomics of BMF and the impact of BMF on hematopoietic niche function during HSCT.
Dr. Blobel investigates the fundamental mechanisms involving transcription factors, chromatin regulators, and higher order chromatin. He is gearing his basic science discoveries towards genetic and epigenetic treatment modalities. In addition, Dr. Blobel is interested in mechanism of epigenetic memory.
The 2014 Penn Medicine Awards of Excellence recognize faculty from The Perelman School of Medicine who exemplify the highest values of innovation, commitment to service, leadership, dedication to patient care, and scholarship and teaching.
Investigators at The Children’s Hospital of Philadelphia are exploring a new gene therapy approach that aims to reactivate the production of fetal hemoglobin as a potential intervention for patients with sickle cell disease.
In a recent interview with the National Initiative for Children's Healthcare Quality (NICHQ), Kwaku Ohene-Frempong, MD, Doctor Emeritus of CHOP's Comprehensive Sickle Cell Center, discussed his work with sickle cell disease. Dr. Ohene-Frempong, who has worked for more than thirty years to improve sickle cell disease treatments in the U.S. and abroad, noted that in Africa sickle cell disease is
Pioneering new approaches to diagnosis, care, and treatment for patients with red blood cell disorders with novel gene therapies and stem-cell-based treatments that aim to reduce symptoms and prolong life.